8.41

0.12% -0.02

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $8.41, with a volume of 243.17K. It is down -0.12% in the last 24 hours and up +12.57% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$8.43

Open:

$8.41

24h Volume:

243.17K

Relative Volume:

0.25

Market Cap:

$1.33B

Revenue:

$61.10M

Net Income/Loss:

$-138.36M

P/E Ratio:

-6.2296

EPS:

-1.35

Net Cash Flow:

$-90.59M

1W Performance:

+14.71%

1M Performance:

+12.57%

6M Performance:

-6.44%

1Y Performance:

-12.20%

1-Day Range:

$8.32

$8.53

1-Week Range:

$7.25

$8.92

52-Week Range:

$4.06

$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

274

Twitter

@OCUTX

Next Earnings Date

2025-03-03

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	8.42	1.33B	61.10M	-138.36M	-90.59M	-1.35
VRTX Vertex Pharmaceuticals Inc	502.50	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	686.06	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.91	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.49	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.40	26.76B	3.32B	-860.46M	-1.04B	-8.32

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

Mar 12, 2025

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL

Mar 12, 2025

Ocular rises as Needham issues new Buy on lead candidate - MSN

Mar 12, 2025

Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World

Mar 12, 2025

Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World

Mar 12, 2025

Mar 11, 2025

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - Benzinga

Mar 11, 2025

Needham Initiates Ocular Therapeutix at Buy With $15 Price Target -March 11, 2025 at 07:30 am EDT - Marketscreener.com

Mar 11, 2025

This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 11, 2025

Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq

Mar 11, 2025

Ocular Therapeutix initiated with a Buy at Needham - TipRanks

Mar 11, 2025

Mar 10, 2025

Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 07, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2025

Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan

Mar 07, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Mar 07, 2025

HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World

Mar 07, 2025

Mar 06, 2025

Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha

Mar 06, 2025

Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World

Mar 06, 2025

Mar 05, 2025

Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire

Mar 05, 2025

Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - MSN

Mar 05, 2025

Truist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Mar 05, 2025

Traders Purchase High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL) - Defense World

Mar 05, 2025

Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus.com

Mar 05, 2025

Mar 04, 2025

Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR

Mar 04, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025

Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness - TipRanks

Mar 04, 2025